Visit our community blood centers in Illinois, Indiana, Michigan and Wisconsin.
About Us Careers Events Customer Service Newsroom
Request more information about our IDH1 and IDH2 tests below.
These two companion diagnostic tests can aid in identifying AML patients that may be treated with the FDA approved drugs TIBSOVO® (ivosidenib) and IDHIFA® (enasidenib).
Complete the short form below and we will contact you with more information on these exciting new tests and what Versiti Diagnostic Laboratories can offer your laboratory needs.
Versiti offers the companion diagnostic test for IDH1 (isocitrate dehydrogenase-1) mutations in acute myeloid leukemia (AML). The method uses the Abbott RealTime IDH1 assay which is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of single nucleotide variants (SNVs) coding five IDH1 mutations (R132C, R132H, R132G, R132S, and R132L) in DNA extracted from human bone marrow or blood.
The companion diagnostic test for IDH2 (isocitrate dehydrogenase-2) mutations in acute myeloid leukemia (AML). Abbott RealTime IDH2 detects single nucleotide variants (SNVs) coding nine IDH2 mutations (R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W) in DNA extracted from human bone marrow or blood. Versiti performs this highly sensitive test and delivers results with turnaround times which could facilitate rapid treatment decisions for patients.
By utilizing the companion diagnostic tests for IDH1 and IDH2 mutations, physicians can make treatment decisions for their patients. The high sensitivity and fast TAT provide a quick analysis of the patient’s genetic mutations and the potential to use a companion diagnostic test.
IDH1 Abbott Realtime PCR test (Test Code: 7647)
This new test is indicated as an aid in identifying acute myeloid leukemia (AML) patients with an isocitrate dehydrogenase-1 (IDH1) mutation for treatment with TIBSOVO® (ivosidenib). Learn More.